# Peptides for injury and tissue repair

Source: https://aminodesk.com/goals/injury-recovery
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

BPC-157 and TB-500 are the best-known repair peptides, and both can now be compounded on prescription. Neither has a controlled human trial showing that it heals an injury.

**The short version**

- **BPC-157:** the published human record is three small studies with fewer than 20 participants in total.
- **TB-500:** no completed human trials of the fragment itself. The studies cited in marketing used a different, larger molecule.
- **Legal status:** since the October 30, 2026 policy, state-licensed pharmacies may compound BPC-157, TB-500 and KPV on an individual prescription. That is not FDA approval.
- **Blends:** a vial mixing several peptides falls outside that policy. See [blends and stacks](https://aminodesk.com/stacks).
- **Athletes:** BPC-157 and TB-500 are prohibited in sport.

## Little or no human evidence

### [BPC-157](https://aminodesk.com/library/bpc-157)

Grade C 2026 policy

The best-known repair peptide, now legally compoundable. Almost all of its evidence is animal work, and an investigation found most of it came from a single lab.

### [LL-37 (cathelicidin)](https://aminodesk.com/library/ll-37)

Grade C No legal route

The body's own antimicrobial peptide. Tested only as a wound treatment, with one positive and one negative trial; the injectable version sold online is unstudied.

### [GHK-Cu and the Glow stack](https://aminodesk.com/library/ghk-cu)

Grade C Mixed

A copper peptide with genuine evidence in skincare, where it is sold as a cosmetic. The injectable version is a different proposition and awaits FDA review.

### [TB-500](https://aminodesk.com/library/tb-500)

Grade D 2026 policy

Related to thymosin beta-4 and usually paired with BPC-157. Legally compoundable since October 2026; human evidence for healing is essentially absent.

### [KPV](https://aminodesk.com/library/kpv)

Grade D 2026 policy

A three-amino-acid peptide taken orally or applied to skin, marketed for gut and skin inflammation. Covered by the 2026 policy, with thin human data.

## What you can legally get

- **Compoundable on prescription under the October 2026 policy:** [BPC-157](https://aminodesk.com/library/bpc-157), [TB-500](https://aminodesk.com/library/tb-500), [KPV](https://aminodesk.com/library/kpv)
- **Depends on the form (see the page):** [GHK-Cu and the Glow stack](https://aminodesk.com/library/ghk-cu)
- **No legal route in the US:** [LL-37 (cathelicidin)](https://aminodesk.com/library/ll-37)

Products sold online as "research use only" are outside every one of these routes. See [how to vet a provider](https://aminodesk.com/providers).

## Keep reading

- [BPC-157 vs TB-500](https://aminodesk.com/compare/bpc-157-vs-tb-500)
- [Blends and stacks](https://aminodesk.com/stacks)
- [Mixing and injecting safely](https://aminodesk.com/guides/mixing-and-injecting)
- [Filter all 40 compounds by goal and legal status](https://aminodesk.com/finder)

This page summarizes our compound pages. The sources for every claim are listed on each of those pages.

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
